Health Care and FDA Changes Expected Under Trump Administration

Life sciences partner Albert Cacozza and health care partner Thomas Bulleit (both of Washington, D.C.) were cited in Jan. 6 JD Supra Business Advisor articles on a Ropes & Gray two-part podcast about some likely results of coming changes to the U.S. Department of Health and Human Services, including the Centers for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA), under the Trump administration.

Mr. Cacozza and Mr. Bulleit note that there are likely to be many important, if not entirely predictable, changes ahead, and specifically that the nomination of Representative Tom Price to be Health and Human Services Secretary creates some uncertainty on the future of value-based health care, that the outlook for FDA regulation approval of drugs and devices may improve under the 21st Century Cures Act as implemented by a Trump FDA, and that the prospects for some action on prescription drug pricing may be stronger than any time in recent years.

Link to JD Supra Business Advisor Part 2